4,7-Dioxobenzothiazole-2-Carboxamide Derivatives, Their Preparation And Their Therapeutic Uses

Abstract

A subject of the present invention is 4,7-dioxobenzothiazole-2-carboxamide derivatives, which inhibit the cdc25 phosphatases, in particular cdc25-C phosphatase. These compounds can in particular be used in the treatment of cancer.

1 - 10 . (canceled) 
     
     
         11 . A method of treating a disease or disorder comprising administering a compound of formula (I) 
       
         
           
           
               
               
           
         
         in racemic, enantiomeric form or a combination thereof, wherein: 
         R 1  is a hydrogen atom, alkyl, alkoxyalkyl, alkylthioalkyl, cycloalkyl, —(CH 2 )—X—Y, —(CH 2 )—Z—NR 6 R 7  radical or a —CHR 8 R 9  radical, 
         X is a bond or a linear or branched alkylene radical comprising 1 to 5 carbon atoms, 
         Y is a saturated cyclic carbon system comprising 1 to 3 condensed rings, wherein each ring independently comprises 3 to 7 members, or Y is a saturated heterocycle comprising 1 to 2 heteroatoms including O, N or S and attached to X by an N or CH member, said saturated heterocycle comprising 2 to 6 additional members, each independently including —CHR 10 —, —CO—, —NR 11 —, —O— or —S—, R 10  is a hydrogen atom or an alkyl radical and R 11  is a hydrogen atom or an alkyl or aralkyl radical, or Y is a carbocyclic or heterocyclic aryl radical optionally substituted by 1 to 3 substituents including a halogen atom, an alkyl radical, a haloalkyl radical, an alkoxy radical, a haloalkoxy radical, a hydroxy radical, a nitro radical, a cyano radical, a phenyl radical, an SO 2 NHR 12  radical or NR 13 R 14  radical, R 12  is a hydrogen atom or an alkyl or phenyl radical, and R 13  and R 14  are each independently-alkyl radicals, 
         Z is a bond or a linear or branched alkylene radical comprising 1 to 5 carbon atoms, 
         R 6  and R 7  are each independently a hydrogen atom, an alkyl, aralkyl or —(CH 2 ) n —OH radical, wherein n is an integer from 1 to 6, or R 6  is an alkoxycarbonyl, haloalkoxycarbonyl or aralkoxycarbonyl radical and R 7  is a hydrogen atom or a methyl radical, or R 6  and R 7 , together with the nitrogen atom to which they are attached, form a heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, wherein the members necessary for completing the heterocycle are each independently —CR 15 R 16 —, —O—, —S— or —NR 17 — radicals, R 15  and R 16  are each independently a hydrogen atom or an alkyl radical, and R 17  is a hydrogen atom, Of an alkyl, or aralkyl radical, or R 17  is a phenyl radical optionally substituted by 1 to 3 substituents including a halogen atom, an alkyl or alkoxy radical, 
         R 8  and R 9 , together with the carbon atom to which they are attached, form an indanyl or tetralinyl radical, or R 8  and R 9 , together with the carbon atom to which they are attached, form a saturated heterocycle comprising 5 to 7 members and 1 to 2 heteroatoms including O, N or S, wherein the nitrogen atoms of said heterocycle are optionally substituted by alkyl radicals or a benzyl radical; 
         R 2  is a hydrogen atom, an alkyl radical, or an aralkyl radical; 
         or R 1  and R 2 , together with the nitrogen atom to which they are attached, form a heterocycle with 4 to 8 members comprising 1 to 2 heteroatoms, wherein the members necessary for completing the heterocycle are each independently —CR 18 R 19 —, —O—, —S— or —NR 20 — radicals, R 18  and R 19  are each independently a hydrogen atom or an alkyl radical, and R 20  is a hydrogen atom, an alkyl radical, or an aralkyl radical; 
         R 3  is a hydrogen atom or a halogen atom; 
         R 4  is an alkyl radical, a haloalkyl radical, a cycloalkyl radical, a cycloalkylalkyl radical, an alkoxyalkyl radical, carbocyclic or heterocyclic aryl radicals or carbocyclic or heterocyclic aralkyl radicals the aryl nucleus of which is optionally substituted by 1 to 3 substituents independently including a halogen atom, an alkyl radical, an alkoxy radical, a haloalkyl radical or —SO 2 —NH 2  radical, 
         or R 4  is —(CH 2 ) m —[O—(CH 2 ) p ] q —O-Alk, —(CH 2 ) r —[O-(CH 2 ) s ] t —NR 21 R 22  or —(CH 2 ) v -A, wherein m, p and s are each independently an integer from 2 to 4, q is an integer from 1 to 4, t is an integer from 0 to 4, r is an integer from 2 to 12 and v is an integer from 1 to 12, Alk is an alkyl radical, R 21  is a hydrogen atom, an alkyl, alkoxycarbonyl, or aralkoxycarbonyl radical, R 22  is a hydrogen atom or an alkyl radical and A is a saturated heterocycle comprising 1 to 2 heteroatoms independently including O, N or S and attached to the —(CH 2 ) v — group by an N or CH member, said saturated heterocycle including 2 to 6 additional members independently including —CHR 23 —, —CO—, —NR 24 —, —O— or —S—, R 23  is a hydrogen atom or an alkyl radical and R 24  is a hydrogen atom, an alkyl radical, an alkoxycarbonyl, or aralkoxycarbonyl group, 
         or R 4  is 
       
       
         
           
           
               
               
           
         
         wherein R 1 , R 2 , and R 3  are as defined above, and L is —(CH 2 ) g —[O—(CH 2 ) w ] x —[O—(CH 2 ) y ] z — or —(CH 2 ) a —Ω—(CH 2 ) b —, wherein g, w and y are integers from 2 to 4, x is an integer from 1 to 3 and z is 0 or 1, a and b are independently integers from 2 to 6 and Ω is —O—, —S—, —NR 25 —, —CO—, —CO—NR 26 —, —CR 27 R 25 —, a cycloalkylene radical containing 3 to 7 carbon atoms, or a carbocyclic aryl radical, R 25  is an alkyl radical, R 26  is a hydrogen atom or a methyl radical, R 27  and R 25  are each independently a hydrogen atom or a methyl group; 
         or R 4  is 
       
       
         
           
           
               
               
           
         
         R 5  is a hydrogen atom, an alkyl, or aralkyl radical, or R 5  is the same as R 4  when R 4  is an alkyl, haloalkyl, alkoxyalkyl, carbocyclic or heterocyclic aralkyl radical, the aryl nucleus of which is optionally substituted by 1 to 3 substituents independently including a halogen atom, an alkyl radical, an alkoxy radical, a haloalkyl radical or a —SO 2 —NH 2  radical; 
         or R 4  and R 5 , together with the nitrogen atom to which they are attached, form a saturated heterocycle with 4 to 7 members comprising 1 to 2 heteroatoms, wherein the members necessary for completing the heterocycle are each independently —CR 29 R 30 —, —O—, —S— or —NR 31 —, R 29  and R 30  are a hydrogen atom, an alkyl, or aralkyl radical and R 31  is —COR 32  or —SO 2 R 33 , 
         R 32  is an alkyl radical, a carbocyclic aryl radical optionally substituted by 1 to 3 substituents including a halogen atom, an alkyl radical, or an alkoxy radical, or R 32  is a heterocyclic aryl radical or a saturated heterocycle comprising 5 to 7 members and 1 to 2 heteroatoms including O, N or S, 
         R 33  is a hydrogen atom or an alkyl radical, 
         or R 4  and R 5 , together with the nitrogen atom to which they are attached, form a heterocyclic aryl radical including 
       
       
         
           
           
               
               
           
         
         the aromatic ring of which may be substituted by 1 to 3 substituents including an alkyl radical or an alkoxy radical; or a salt thereof, wherein the disease or disorder is a tumorous proliferative disease, non-tumorous proliferative disease, neurodegenerative disease, parasitic disease, viral infection, spontaneous alopecia, alopecia induced by exogenous products, radiation-induced alopecia, auto-immune disease, transplant rejection, inflammatory disease or allergy. 
       
     
     
         12 . The method according to  claim 11 , wherein R 4  is not 
       
         
           
           
               
               
           
         
       
       or salt thereof. 
     
     
         13 . The method according to  claim 11 , wherein R 4  is 
       
         
           
           
               
               
           
         
       
       or a salt thereof. 
     
     
         14 . The method according to  claim 11 , wherein the compound is:
 5-{[2-(dimethylamino)ethyl]amino}-2-(morpholin-4-ylcarbonyl)-1,3-benzothiazole-4,7-dione;   tert-butyl{2-[2-(2-{[(5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazol-2-yl)carbonyl]amino}ethoxy)ethoxy]ethyl}carbamate;   N,N-dibenzyl-5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   5-{[2-(dimethylamino)ethyl]amino}-N,N-bis(2-methoxyethyl)-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-N-[3-(2-oxopyrrolidin-1-yl)propyl]-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   4,7-dioxo-N-[3-(2-oxopyrrolidin-1-yl)propyl]-5-[(2-pyrrolidin-1-ylethyl)amino]-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   5-{[2-(dimethylamino)ethyl]amino}-N-isobutyl-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   tert-butyl (4-{[(5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazol-2-yl)carbonyl]amino}butyl)carbamate;   5-{[2-(dimethylamino)ethyl]amino}-2-{[4-(2-furoyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-N-(2-methoxyethyl)-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N-butyl-5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N-benzyl-5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N-(cyclohexylmethyl)-5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N,N′-(oxydiethane-2,1-diyl)bis(5-([2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide);   N,N′-[ethane-1,2-diylbis(oxyethane-2,1-diyl)]bis(5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide);   5-{[2-(dimethylamino)ethyl]amino}-2-{[4-(morpholin-4-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   2-{[4-(morpholin-4-ylcarbonyl)piperazin-1-yl]carbonyl}-5-[(2-pyrrolidin-1-ylethyl)amino]-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-N-(4-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   5-{[2-(dimethylamino)ethyl]amino}-2-{[4-(methylsulphonyl)piperazin-1-yl]carbonyl]-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   6-bromo-5-{[2-(dimethylamino)ethyl]amino}-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-2-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-2-{[4-(2-thienylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-N-ethyl-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N-(4-chlorophenyl)-5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N-1,3-benzodioxol-5-yl-5-{[2-(dimethylamino)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   5-[(2-methoxyethyl)amino]-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-(4-methylpiperazin-1-yl)-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3 -benzothiazole-4,7-dione;   5-[(2-pyridin-2-ylethyl)amino]-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-[(3-morpholin-4-ylpropyl)amino]-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-[(1-benzylpyrrolidin-3-yl)amino]-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-[(2-cyclohexylethyl)amino]-2-{[4-(tetrahydrofuran-2-ylcarbonyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-N-(4-fluorophenyl)-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   6-{[2-(dimethylamino)ethyl]amino}-2-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl]amino}-N-(3-fluoro-4-methoxyphenyl)-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   5-{[2-dimethylamino)ethyl]amino}-2-[(6-methoxy-3,4-dihydroquinolin-1(2H)-yl)carbonyl]-1,3-benzothiazole-4,7-dione;   5-{(2-(dimethylamino)ethyl]amino}-2-{[4-(4-methoxybenzoyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione;   5-{[2-(dimethylamino)ethyl](methyl)amino]-N-ethyl-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   N-ethyl-5-{[2-(4-fluorophenyl)ethyl]amino}-4,7-dioxo-4,7-dihydro-1,3-benzothiazole-2-carboxamide;   or a salt thereof.   
     
     
         15 . The method according to  claim 11 , wherein the disease or disorder is cancer. 
     
     
         16 . The method according to  claim 15 , wherein the cancer is breast cancer, lymphomas, cancers of the neck or head, lung cancer, cancer of the colon, cancer of the prostate or cancer of the pancreas. 
     
     
         17 . The method according to  claim 11 , wherein the compound is—5-{[2-(dimethylamino)ethyl]amino}-2-{[4(2-furoyl)piperazin-1-yl]carbonyl}-1,3-benzothiazole-4,7-dione or a salt thereof. 
     
     
         18 . The method according to  claim 11 , wherein the compound is—6-{[2-(dimethylamino)ethyl]amino}-2-(pyrrolidin-1-ylcarbonyl)-1,3-benzothiazole-4,7-dione or a salt thereof.